{"id":"sb206-10-3-berdazimer","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site irritation"},{"rate":null,"effect":"Application site erythema"},{"rate":null,"effect":"Application site pruritus"}]},"_chembl":{"chemblId":"CHEMBL4298064","moleculeType":"Small molecule"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Berdazimer is a diazeniumdiolate compound that releases nitric oxide when applied topically. Nitric oxide has broad-spectrum antimicrobial activity against bacteria, viruses, and fungi, while also reducing inflammation and promoting wound healing. This mechanism makes it suitable for treating various viral skin infections.","oneSentence":"Berdazimer is a nitric oxide-releasing topical agent that generates nitric oxide to exert antimicrobial and anti-inflammatory effects on skin lesions.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:33:31.973Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Molluscum contagiosum (topical treatment)"},{"name":"Other viral skin infections"}]},"trialDetails":[{"nctId":"NCT04535531","phase":"PHASE3","title":"A Phase 3 Molluscum Contagiosum Efficacy and Safety Study","status":"COMPLETED","sponsor":"Novan, Inc.","startDate":"2020-09-01","conditions":"Molluscum Contagiosum","enrollment":891}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SB206 12% berdazimer sodium"],"phase":"phase_3","status":"active","brandName":"SB206 10.3% berdazimer","genericName":"SB206 10.3% berdazimer","companyName":"Novan, Inc.","companyId":"novan-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SB206 10.3% berdazimer is a small molecule that releases nitric oxide (NO) and has antimicrobial properties. It is being studied as a treatment for Molluscum Contagiosum in a Phase 3 clinical trial (NCT04535531) where it is compared to a vehicle gel.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}